{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:40:43Z","timestamp":1792802443077,"version":"4.5.0"},"reference-count":76,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License.","id":[{"id":"https:\/\/ror.org\/02ed4cj64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<p>Transthyretin (TTR) is a tetrameric protein, synthesized primarily by the liver, that acts as a physiological transport protein for retinol and thyroxine. TTR can misfold into pathogenic amyloid fibrils that deposit in the heart and nerves, causing a life-threatening transthyretin amyloidosis cardiomyopathy (ATTR-CM), and a progressive and debilitating polyneuropathy (ATTR-PN). Recent therapeutic advances have resulted in the development of drugs that reduce TTR production. Patisiran is a small interfering RNA that disrupts the complimentary mRNA and inhibits TTR synthesis, and is the first gene-silencing medication licensed for the treatment of ATTR amyloidosis. After encouraging results following the use of patisiran for the treatment of patients with ATTR-PN, there has been increasing interest in the use of patisiran for the treatment of ATTR-CM. Various studies have demonstrated improvements across a wide range of cardiac biomarkers following treatment with patisiran, and have changed the perception of ATTR-CM from being thought of as a terminal disease process, to now being regarded as a treatable disease. These successes represent a huge milestone and have the potential to revolutionize the landscape of treatment for ATTR-CM. However, the long-term safety of patisiran and how best to monitor cardiac response to treatment remain to be determined.<\/p>","DOI":"10.17925\/hi.2023.17.1.27","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T10:16:28Z","timestamp":1688206588000},"page":"27","source":"Crossref","is-referenced-by-count":23,"title":["Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy"],"prefix":"10.17925","volume":"17","author":[{"given":"Adam","family":"Ioannou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Amyloidosis Centre, University College London, Royal Free Campus, London, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Amyloidosis Centre, University College London, Royal Free Campus, London, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D","family":"Gillmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Amyloidosis Centre, University College London, Royal Free Campus, London, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis.\n                      Lancet\n                      . 2016;387:2641\u201354. DOI: 10.1016\/S0140-6736(15)01274-X","DOI":"10.1016\/S0140-6736(15)01274-X"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Hawkins PN. Systemic amyloidosis.\n                      Curr Opin Pharmacol\n                      . 2006;6:214\u201320. DOI: 10.1016\/j.coph.2005.10.005","DOI":"10.1016\/j.coph.2005.10.005"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis.\n                      Clin Med (Lond\n                      ). 2018;18:s30\u20135. DOI: 10.7861\/clinmedicine.18-2-s30","DOI":"10.7861\/clinmedicine.18-2-s30"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Fontana M, \u0106orovi\u0107 A, Scully P, Moon JC. Myocardial amyloidosis: The exemplar interstitial disease.\n                      JACC Cardiovasc Imaging\n                      . 2019;12:2345\u201356. DOI: 10.1016\/j. jcmg.2019.06.023","DOI":"10.1016\/j.jcmg.2019.06.023"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Koike H, Katsuno M. Transthyretin amyloidosis: Update on the clinical spectrum, pathogenesis, and disease-modifying therapies.\n                      Neurol Ther\n                      . 2020;9:317\u201333. DOI: 10.1007\/s40120-020-00210-7","DOI":"10.1007\/s40120-020-00210-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis.\n                      Cardiovasc Res\n                      . 2022;118:3517\u201335. DOI: 10.1093\/cvr\/cvac119","DOI":"10.1093\/cvr\/cvac119"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Patel RK, Ioannou A, Razvi Y, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy-from diagnosis to prognosis.\n                      Eur J Heart Fail\n                      . 2022;24:2355\u201363. DOI: 10.1002\/ejhf.2646","DOI":"10.1002\/ejhf.2646"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ioannou A, Patel R, Gillmore JD, Fontana M. Imaging-guided treatment for cardiac amyloidosis.\n                      Curr Cardiol Rep\n                      . 2022;24:839\u201350. DOI: 10.1007\/s11886-022-01703-7","DOI":"10.1007\/s11886-022-01703-7"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ioannou A, Patel RK, Razvi Y, et al. Multi-imaging characterization of cardiac phenotype in different types of amyloidosis.\n                      JACC Cardiovasc Imaging\n                      . 2022;16:464\u201377. DOI: 10.1016\/j.jcmg.2022.07.008","DOI":"10.1016\/j.jcmg.2022.07.008"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis.\n                      J Am Coll Cardiol\n                      . 2017;70:466\u201377. DOI: 10.1016\/j.jacc.2017.05.053","DOI":"10.1016\/j.jacc.2017.05.053"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis.\n                      J Am Coll Cardiol\n                      . 2019;73:1733\u20134. DOI: 10.1016\/j.jacc.2019.01.035","DOI":"10.1016\/j.jacc.2019.01.035"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Carr AS, Pelayo-Negro AL, Evans MRB, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK.\n                      J Neurol Neurosurg Psychiatry\n                      . 2016;87:620\u20137. DOI: 10.1136\/jnnp-2015-310907","DOI":"10.1136\/jnnp-2015-310907"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis.\n                      Mod Pathol\n                      . 2015;28:201\u20137. DOI: 10.1038\/modpathol.2014.102","DOI":"10.1038\/modpathol.2014.102"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Geller HI, Singh A, Alexander KM, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis.\n                      JAMA\n                      . 2017;318:962\u20133. DOI: 10.1001\/jama.2017.9236","DOI":"10.1001\/jama.2017.9236"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis.\n                      Cardiol Ther\n                      . 2021;10:289\u2013311. DOI: 10.1007\/s40119-021-00222-w","DOI":"10.1007\/s40119-021-00222-w"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis.\n                      Amyloid\n                      . 2013;20:263\u20138. DOI: 10.3109\/13506129.2013.845745","DOI":"10.3109\/13506129.2013.845745"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Porcari A, Razvi Y, Masi A, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.\n                      Eur J Heart Fail\n                      . 2023;25:515\u201324. DOI: 10.1002\/ejhf.2776.","DOI":"10.1002\/ejhf.2776"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.\n                      Circulation\n                      . 2016;133:2404\u201312. DOI: 10.1161\/CIRCULATIONAHA.116.021612","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type Transthyretin Amyloidosis as a cause of heart failure with preserved ejection fraction.\n                      Eur Heart J\n                      . 2015;36:2585\u201394. DOI: 10.1093\/eurheartj\/ehv338.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Rauf MU, Hawkins PN, Cappelli F, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.\n                      Eur Heart J\n                      . 2023;ehad139. DOI: 10.1093\/eurheartj\/ehad139","DOI":"10.1093\/eurheartj\/ehad139"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ioannou A, Patel RK, Razvi Y, et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years.\n                      Circulation\n                      . 2022;146:1657\u201370. DOI: 10.1161\/CIRCULATIONAHA.122.060852","DOI":"10.1161\/CIRCULATIONAHA.122.060852"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lauppe RE, Liseth Hansen J, Gerdeskold C, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden.\n                      Open Heart\n                      . 2021;8:e001755. DOI: 10.1136\/openhrt-2021-001755","DOI":"10.1136\/openhrt-2021-001755"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study.\n                      Ann Med\n                      . 2008;40:232\u20139. DOI: 10.1080\/07853890701842988","DOI":"10.1080\/07853890701842988"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Adams D, Algalarrondo V, Polydefkis M, et al. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.\n                      Orphanet J Rare Dis\n                      . 2021;16:411. DOI: 10.1186\/s13023-021-01960-9","DOI":"10.1186\/s13023-021-01960-9"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: Issues and challenges.\n                      Liver Transpl\n                      . 2015;21:282\u201392. DOI: 10.1002\/lt.24058","DOI":"10.1002\/lt.24058"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.\n                      N Engl J Med\n                      . 2018;379:1007\u201316. DOI: 10.1056\/NEJMoa1805689","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis.\n                      N Engl J Med\n                      . 2007;356:2361\u201371. DOI: 10.1056\/NEJMoa070265","DOI":"10.1056\/NEJMoa070265"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes.\n                      J Clin Oncol\n                      . 2012;30:4541\u20139. DOI: 10.1200\/JCO.2011.37.7614","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.\n                      N Engl J Med\n                      . 2018;379:11\u201321. DOI: 10.1056\/NEJMoa1716153","DOI":"10.1056\/NEJMoa1716153"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.\n                      N Engl J Med\n                      . 1990;323:508\u201313. DOI: 10.1056\/NEJM199008233230803","DOI":"10.1056\/NEJM199008233230803"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Martinez-Naharro A, Patel R, Kotecha T, et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.\n                      Eur Heart J\n                      . 2022;43:4722\u201335. DOI: 10.1093\/eurheartj\/ehac363","DOI":"10.1093\/eurheartj\/ehac363"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Urits I, Swanson D, Swett MC, et al. A review of patisiran (ONPATTROR) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis.\n                      Neurol Ther\n                      . 2020;9:301\u201315. DOI: 10.1007\/s40120-020-00208-1","DOI":"10.1007\/s40120-020-00208-1"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Setten RL, Rossi JJ, Han S-P. The current state and future directions of RNAi-based therapeutics.\n                      Nat Rev Drug Discov\n                      . 2019;18:421\u201346. DOI: 10.1038\/s41573-019-0017-4","DOI":"10.1038\/s41573-019-0017-4"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: State of the art.\n                      Signal Transduct Target Ther\n                      . 2020;5:101. DOI: 10.1038\/s41392-020-0207-x.","DOI":"10.1038\/s41392-020-0207-x"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Caplen NJ, Mousses S. Short interfering RNA (siRNA) -mediated RNA interference (RNAi) in human cells.\n                      Ann N Y Acad Sci\n                      . 2003;1002:56\u201362. DOI: 10.1196\/annals.1281.007","DOI":"10.1196\/annals.1281.007"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: State-of-the-art and future perspectives.\n                      BioDrugs\n                      . 2022;36:549\u201371. DOI: 10.1007\/s40259-022-00549-3","DOI":"10.1007\/s40259-022-00549-3"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis.\n                      N Engl J Med\n                      . 2013;369:819\u201329. DOI: 10.1056\/NEJMoa1208760","DOI":"10.1056\/NEJMoa1208760"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study.\n                      Orphanet J Rare Dis\n                      . 2015;10:109. DOI: 10.1186\/s13023-015-0326-6","DOI":"10.1186\/s13023-015-0326-6"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Coelho T, Adams D, Conceicao I, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.\n                      Orphanet J Rare Dis\n                      . 2020;15:179. DOI: 10.1186\/s13023-020-01399-4","DOI":"10.1186\/s13023-020-01399-4"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Gonzalez-Duarte A, Berk JL, Quan D, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.\n                      J Neurol\n                      . 2020;267:713\u20134. DOI: 10.1007\/s00415-020-09715-5","DOI":"10.1007\/s00415-020-09715-5"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis.\n                      Circulation\n                      . 2019;139:431\u201343. DOI: 10.1161\/CIRCULATIONAHA.118.035831","DOI":"10.1161\/CIRCULATIONAHA.119.040941"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression.\n                      JACC Cardiovasc Imaging\n                      . 2021;14:189\u201399. DOI: 10.1016\/j.jcmg.2020.07.043","DOI":"10.1016\/j.jcmg.2020.07.043"},{"key":"ref43","unstructured":"Alnylam Pharmaceuticals, Inc. Topline results from APOLLO-B phase 3 study of Patisiran. 2022. Available at: https:\/\/alny lampharmaceuticalsinc.gcs-web.com\/static-files\/dc61b882-9346-4394-9f5c-dd322727742b (Date last accessed: 6 June 2023)."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Maurer MS, Fontana M, Berk J, et al. Primary results from APOLLO-B, a phase 3 study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy.\n                      Journal of Cardiac Failure\n                      . 2023;29:550. DOI: 10.1016\/j. cardfail.2022.10.013","DOI":"10.1016\/j.cardfail.2022.10.013"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis.\n                      BioDrugs\n                      . 2023;37:127\u201342. DOI: 10.1007\/s40259-023-00577-7","DOI":"10.1007\/s40259-023-00577-7"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Merlini G, Lousada I, Ando Y, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.\n                      Leukemia\n                      . 2016;30:1979\u201386. DOI: 10.1038\/leu.2016.191","DOI":"10.1038\/leu.2016.191"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Emdin M, Passino C, Prontera C, et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure.\n                      Clin Chem Lab Med\n                      . 2004;42:627\u201336. DOI: 10.1515\/CCLM.2004.108","DOI":"10.1515\/CCLM.2004.108"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: An equilibrium contrast cardiovascular magnetic resonance study.\n                      Circ Cardiovasc Imaging\n                      . 2013;6:34\u20139. DOI: 10.1161\/CIRCIMAGING.112.978627","DOI":"10.1161\/CIRCIMAGING.112.978627"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Passino C, Aimo A, Masotti S, et al. Cardiac troponins as biomarkers for cardiac disease.\n                      Biomark Med\n                      . 2019;13:325\u201330. DOI: 10.2217\/bmm-2019-0039","DOI":"10.2217\/bmm-2019-0039"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Gertz MA, Kumar SK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.\n                      Heart\n                      . 2014;100:383\u20138. DOI: 10.1136\/heartjnl-2013-304957","DOI":"10.1136\/heartjnl-2013-304957"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Chacko L, Karia N, Venneri L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022;24:1700\u201312. DOI: 10.1002\/ejhf.2606","DOI":"10.1002\/ejhf.2606"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Dey D, Slomka PJ, Leeson P, et al. Artificial intelligence in cardiovascular imaging.\n                      J Am Coll Cardiol\n                      . 2019;73:1317\u201335. DOI: 10.1016\/j.jacc.2018.12.054","DOI":"10.1016\/j.jacc.2018.12.054"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Tromp J, Seekings PJ, Hung C-L, et al. Automated interpretation of systolic and diastolic function on the echocardiogram: A multicohort study.\n                      Lancet Digit Health\n                      . 2022;4:e46\u201354. DOI: 10.1016\/S2589-7500(21)00235-1","DOI":"10.1016\/S2589-7500(21)00235-1"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Howard JP, Francis DP. Machine learning with convolutional neural networks for clinical cardiologists.\n                      Heart\n                      . 2021;108:973\u201381. DOI: 10.1136\/heartjnl-2020-318686","DOI":"10.1136\/heartjnl-2020-318686"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis.\n                      JACC Cardiovasc Imaging\n                      . 2014;7:157\u201365. DOI: 10.1016\/j.jcmg.2013.10.008","DOI":"10.1016\/j.jcmg.2013.10.008"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.\n                      JACC Cardiovasc Imaging\n                      . 2013;6:488\u201397. DOI: 10.1016\/j. jcmg.2012.11.013","DOI":"10.1016\/j.jcmg.2012.11.013"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Ioannou A, Patel RK, Martinez-Naharro A, et al. Tracking Multiorgan treatment response in systemic AL-Amyloidosis with cardiac magnetic resonance derived extracellular volume mapping.\n                      JACC Cardiovascular imaging\n                      . 2023;S1936-878X( 23)00116-X. DOI: 10.1016\/j.jcmg.2023.02.019.","DOI":"10.1016\/j.jcmg.2023.02.019"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: A pilot study using 18F-florbetapir positron emission tomography.\n                      Eur J Nucl Med Mol Imaging\n                      . 2014;41:1652\u201362. DOI: 10.1007\/s00259-014-2787-6","DOI":"10.1007\/s00259-014-2787-6"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: A pilot study using 18F-flutemetamol positron emission tomography.\n                      Ann Nucl Med\n                      . 2019;33:624\u20138. DOI: 10.1007\/s12149-019-01372-7","DOI":"10.1007\/s12149-019-01372-7"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET.\n                      J Nucl Med\n                      . 2013;54:213\u201320. DOI: 10.2967\/jnumed.111.102053","DOI":"10.2967\/jnumed.111.102053"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Genovesi D, Vergaro G, Giorgetti A, et al. [ 18F ] -florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions.\n                      JACC Cardiovasc Imaging\n                      . 2021;14:246\u201355. DOI: 10.1016\/j.jcmg.2020.05.031","DOI":"10.1016\/j.jcmg.2020.05.031"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with 18F-florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy.\n                      Eur J Nucl Med Mol Imaging\n                      . 2019;46:1407\u201316. DOI: 10.1007\/s00259-019-04290-y","DOI":"10.1007\/s00259-019-04290-y"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Lee SP, Suh HY, Park S, et al. Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis. J Am Coll Cardiol. 2020;75:380\u201390. DOI: 10.1016\/j. jacc.2019.11.037","DOI":"10.1016\/j.jacc.2019.11.037"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Kim YJ, Ha S, Kim Y-I. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis.\n                      J Nucl Cardiol\n                      . 2020;27:123\u201332. DOI: 10.1007\/s12350-018-1365-x","DOI":"10.1007\/s12350-018-1365-x"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Sousa JC, Marques F, Dias-Ferreira E, et al. Transthyretin influences spatial reference memory.\n                      Neurobiol Learn Mem\n                      . 2007;88:381\u20135. DOI: 10.1016\/j.nlm.2007.07.006","DOI":"10.1016\/j.nlm.2007.07.006"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Brouillette J, Quirion R. Transthyretin: A key gene involved in the maintenance of memory capacities during aging.\n                      Neurobiol Aging\n                      . 2008;29:1721\u201332. DOI: 10.1016\/j. neurobiolaging.2007.04.007","DOI":"10.1016\/j.neurobiolaging.2007.04.007"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation.\n                      Proc Natl Acad Sci U S A\n                      . 1994;91:8368\u201372. DOI: 10.1073\/pnas.91.18.8368","DOI":"10.1073\/pnas.91.18.8368"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways.\n                      J Neurosci\n                      . 2002;22:7380\u20138. DOI: 10.1523\/JNEUROSCI.22-17-07380.2002","DOI":"10.1523\/JNEUROSCI.22-17-07380.2002"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Stein TD, Anders NJ, DeCarli C, et al. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis.\n                      J Neurosci\n                      . 2004;24:7707\u201317. DOI: 10.1523\/JNEUROSCI.2211-04.2004","DOI":"10.1523\/JNEUROSCI.2211-04.2004"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Santos SD, Lambertsen KL, Clausen BH, et al. CSF transthyretin neuroprotection in a mouse model of brain ischemia.\n                      J Neurochem\n                      . 2010;115:1434\u201344. DOI: 10.1111\/j.1471-4159.2010.07047.x","DOI":"10.1111\/j.1471-4159.2010.07047.x"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Gomes JR, Nogueira RS, Vieira M, et al. Transthyretin provides trophic support via megalin by promoting neurite outgrowth and neuroprotection in cerebral ischemia.\n                      Cell Death Differ\n                      . 2016;23:1749\u201364. DOI: 10.1038\/cdd.2016.64","DOI":"10.1038\/cdd.2016.64"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Gao C, Zhang B, Zhang W, et al. Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction.\n                      Clin Exp Med\n                      . 2011;11:49\u201354. DOI: 10.1007\/s10238-010-0103-8","DOI":"10.1007\/s10238-010-0103-8"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Luigetti M, Servidei S. Patisiran in hereditary transthyretin-mediated amyloidosis.\n                      Lancet Neurol\n                      . 2021;20:21\u20133. DOI: 10.1016\/S1474-4422(20)30397-5","DOI":"10.1016\/S1474-4422(20)30397-5"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial.\n                      Amyloid\n                      . 2022;30:1\u20139. DOI: 10.1080\/13506129.2022.2091985","DOI":"10.1080\/13506129.2022.2091985"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Keam SJ. Vutrisiran: First approval.\n                      Drugs\n                      . 2022;82:1419\u201325. DOI: 10.1007\/s40265-022-01765-5","DOI":"10.1007\/s40265-022-01765-5"},{"key":"ref76","unstructured":"ClinicalTrials.gov. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. ClinicalTrials.gov Identifier: NCT04153149. Available at: www. clinicaltrials.gov\/ct2\/show\/NCT04153149 (Date last accessed: 12 September 2022)."}],"container-title":["Heart International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchcardio.com\/cardiovascular-disease\/journal-articles\/patisiran-for-the-treatment-of-transthyretin-mediated-amyloidosis-with-cardiomyopathy\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:58:13Z","timestamp":1764745093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchcardio.com\/cardiovascular-disease\/journal-articles\/patisiran-for-the-treatment-of-transthyretin-mediated-amyloidosis-with-cardiomyopathy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["HI.2023.17.1.27"],"URL":"https:\/\/doi.org\/10.17925\/hi.2023.17.1.27","relation":{},"ISSN":["2036-2579"],"issn-type":[{"value":"2036-2579","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}